CRBN and Miyoshi myopathy: In our study, thalidomide at 0.1 μg/ml targeted to IRES bFGF involving clonogenicity of MM cells as the primary pharmacological target, Instead, thalidomide and pomalidomide even at 10μg/ml concentration did not affect the ubiquitination of cereblon in RPMI8226 MM cells (Figure 5F), indicating that this protein may not be the primary pharmacological target of thalidomide or pomalidomide in MM patients.